Medtronic (NYSE:MDT) said today that it won FDA approval for its implantable drug-delivery system designed to administer United Therapeutics‘ (NSDQ:UTHR) pulmonary arterial hypertension drug, Remodulin.
United Therapeutics is slated to take the lead on commercial promotion of the drug-device system, with support from Medtronic.
Get the full story at our sister site, Drug Delivery Business News.